Outcomes Research in Health Care- Simulations to Drive Cost Conclusions
Jan 1, 2004, 00:00
10.1111/j.1524-4733.2004.71002.x
https://www.valueinhealthjournal.com/article/S1098-3015(10)60176-3/fulltext
Title :
Outcomes Research in Health Care- Simulations to Drive Cost Conclusions
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)60176-3&doi=10.1111/j.1524-4733.2004.71002.x
First page :
Section Title :
Open access? :
No
Section Order :
11
In this issue of Value in Health, Caro and associates report on their development of a simulation to measure the relative costs of two different oral prescription medications for the management of type 2 diabetes mellitus: nateglinide and metformin. The primary finding in the study was that patients treated with nateglinide showed a 3-year treatment cost reduction of $295 in comparison to metformin, primarily owing to a 2.4-month reduction in the time it took patients to achieve dual glycemic control, as measured by postprandial glucose (PPG) and hemoglobin A1c determinations (HbA1c). Of note is the development of a simulation tool that uses previously reported clinical data to apply the efficacy of each of the compared agents.
Categories :
- Cost-comparison, Effectiveness, Utility, Benefit Analysis
- Decision Modeling & Simulation
- Diabetes/Endocrine/Metabolic Disorders
- Economic Evaluation
- Specific Diseases & Conditions
- Study Approaches